Severe pulmonary hypertension associated with COPD: Hemodynamic improvement with specific therapy

Respiration

Volumn 90, Issue 3, 2015, Pages 220-228

  Girard, Anne ^a   Jouneau, Stephane ^a,b   Chabanne, Céline ^a   Khouatra, Chahéra ^c   Lannes, Morgane ^b   Traclet, Julie ^c   Turquier, Ségolène ^c   Delaval, P ^a,b   Cordier, J F ^c,d   Cottin, Vincent ^c,d  

^a Centre de Compétences de l'Hypertension Pulmonaire   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c LOUIS PRADEL HOSPITAL   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

Chronic obstructive pulmonary disease; Echocardiography; Endothelin receptor antagonists; Phosphodiesterase 5 inhibitors; Pulmonary hypertension; Right heart catheterization

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PROSTANOID; SILDENAFIL; SULFONAMIDE; VASODILATOR AGENT;

AGED; ARTERIAL OXYGEN SATURATION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEART CATHETERIZATION; HEART INDEX; HEMODYNAMIC PARAMETERS; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; NEW YORK HEART ASSOCIATION CLASS; OXYGEN THERAPY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; WALKING; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; DRUG EFFECTS; FRANCE; HEMODYNAMICS; HYPERTENSION, PULMONARY; MIDDLE AGED; MULTICENTER STUDY; NONPARAMETRIC TEST; PHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; VASCULAR RESISTANCE;

AGED; COHORT STUDIES; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; FRANCE; HEMODYNAMICS; HOSPITALS, UNIVERSITY; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SILDENAFIL CITRATE; STATISTICS, NONPARAMETRIC; SULFONAMIDES; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 84954383875     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000431380     Document Type: Article

References (40)

1. Mathers CD, Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442
2. Weitzenblum E, Loiseau A, Hirth C, Mirhom R, Rasaholinjanahary J: Course of pulmonary hemodynamics in patients with chronic obstructive pulmonary disease. Chest 1979; 75: 656-662
3. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M: Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981; 36: 752-758
4. Andersen KH, Iversen M, Kjaergaard J, Mortensen J, Nielsen-Kudsk JE, Bendstrup E, Videbaek R, Carlsen J: Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant 2012; 31: 373-380
5. Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Charpentier C, Kessler R: Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995; 107: 1193-1198
6. Thabut G, Dauriat G, Stern JB, Logeart D, Levy A, Marrash-Chahla R, Mal H: Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127: 1531-1536
7. Cuttica MJ, Kalhan R, Shlobin OA, Ahmad S, Gladwin M, Machado RF, Barnett SD, Nathan SD: Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respir Med 2010; 104: 1877-1882
8. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, Ehrhart M, Kessler R, Weitzenblum E: Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 189-194
9. Seeger W, Adir Y, Barbera JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galie N, Ghio S, Gibbs S, Martinez FJ, Semigran MJ, Simonneau G, Wells AU, Vachiery JL: Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013; 62: D109-D116
10. Chaouat A, Naeije R, Weitzenblum E: Pulmonary hypertension in COPD. Eur Respir J 2008; 32: 1371-1385
11. Timms RM, Khaja FU, Williams GW: Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. Ann Intern Med 1985; 102: 29-36
12. Skjorten I, Hilde JM, Melsom MN, Hansteen V, Steine K, Humerfelt S: Pulmonary artery pressure and PaO 2 in chronic obstructive pulmonary disease. Respir Med 2013; 107: 1271-1279
13. Keusch S, Hildenbrand FF, Bollmann T, Halank M, Held M, Kaiser R, Kovacs G, Lange TJ, Seyfarth HJ, Speich R, Ulrich S: Tobacco smoke exposure in pulmonary arterial and thromboembolic pulmonary hypertension. Respiration 2014; 88: 38-45
14. Chaouat A, Savale L, Chouaid C, Tu L, Sztrymf B, Canuet M, Maitre B, Housset B, Brandt C, Le Corvoisier P, Weitzenblum E, Eddahibi S, Adnot S: Role for interleukin-6 in COPD-related pulmonary hypertension. Chest 2009; 136: 678-687
15. Carlsen J, Hasseriis Andersen K, Boesgaard S, Iversen M, Steinbruchel D, Bogelund Andersen C: Pulmonary arterial lesions in explanted lungs after transplantation correlate with severity of pulmonary hypertension in chronic obstructive pulmonary disease. J Heart Lung Transplant 2013; 32: 347-354
16. Carratu P, Scoditti C, Maniscalco M, Seccia TM, Di Gioia G, Gadaleta F, Cardone RA, Dragonieri S, Pierucci P, Spanevello A, Resta O: Exhaled and arterial levels of endothelin-1 are increased and correlate with pulmonary systolic pressure in COPD with pulmonary hypertension. BMC Pulm Med 2008; 8: 20
17. Zielinski J, Tobiasz M, Hawrylkiewicz I, Sliwinski P, Palasiewicz G: Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients: a 6-year prospective study. Chest 1998; 113: 65-70
18. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M, Tamm M: A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008; 32: 619-628
19. Valerio G, Bracciale P, Grazia D Agostino A: Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis 2009; 3: 15-21
20. Rietema H, Holverda S, Bogaard HJ, Marcus JT, Smit HJ, Westerhof N, Postmus PE, Boonstra A, Vonk-Noordegraaf A: Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 2008; 31: 759-764
21. Blanco I, Gimeno E, Munoz PA, Pizarro S, Gistau C, Rodriguez-Roisin R, Roca J, Barbera JA: Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010; 181: 270-278
22. Lederer DJ, Bartels MN, Schluger NW, Brogan F, Jellen P, Thomashow BM, Kawut SM: Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD 2012; 9: 268-275
23. Dernaika TA, Beavin M, Kinasewitz GT: Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respiration 2010; 79: 377-382
24. Boeck L, Tamm M, Grendelmeier P, Stolz D: Acute effects of aerosolized iloprost in COPD related pulmonary hypertension - A randomized controlled crossover trial. PLoS One 2012; 7: e52248
25. Hurdman J, Condliffe R, Elliot CA, Swift A, Rajaram S, Davies C, Hill C, Hamilton N, Armstrong IJ, Billings C, Pollard L, Wild JM, Lawrie A, Lawson R, Sabroe I, Kiely DG: Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J 2013; 41: 1292-1301
26. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365
27. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G: Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111
28. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories: ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117
29. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-S54
30. Sitbon O, Humbert M, Simonneau G: Treatment for pulmonary arterial hypertension under the new French hospital financing system. Recommendations of the Pulmonary Vascular Diseases Working Group of the French Society of Pulmonary Medicine. Presse Med 2005; 34: 1456-1464
31. Boerrigter BG, Bogaard HJ, Trip P, Groepenhoff H, Rietema H, Holverda S, Boonstra A, Postmus PE, Westerhof N, Vonk-Noordegraaf A: Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension. Chest 2012; 142: 1166-1174
32. Held M, Walthelm J, Baron S, Roth C, Jany B: Functional impact of pulmonary hypertension due to hypoventilation and changes under noninvasive ventilation. Eur Respir J 2014; 43: 156-165
33. Cottin V, Lorillou M, Khouatra C, Traclet J, Nesme P, Cordier JF: Pulmonary hypertension specific therapy in patients with chronic respiratory insufficiency. Eur Respir J 2014; 44: 821-822
34. Kontogianni K, Gerovasili V, Gompelmann D, Schuhmann M, Heussel CP, Herth FJ, Eberhardt R: Effectiveness of endobronchial coil treatment for lung volume reduction in patients with severe heterogeneous emphysema and bilateral incomplete fissures: a six-month follow-up. Respiration 2014; 88: 52-60
35. Hegewald MJ, Elliott CG: Sustained improvement with iloprost in a COPD patient with severe pulmonary hypertension. Chest 2009; 135: 536-537
36. Lasota B, Skoczynski S, Mizia-Stec K, Pierzchala W: The use of iloprost in the treatment of out of proportion pulmonary hypertension in chronic obstructive pulmonary disease. Int J Clin Pharm 2013; 35: 313-315
37. Cottin V, Khouatra C, Lazor R, Canu P, Cordier JF: Pulmonary hypertension therapy and COPD: still many questions to be answered. Eur Respir J 2009; 33: 450-452, author reply 2-3
38. Blanco I, Santos S, Gea J, Guell R, Torres F, Gimeno-Santos E, Rodriguez DA, Vilaro J, Gomez B, Roca J, Barbera JA: Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J 2013; 42: 982-992
39. Park J, Song JH, Park DA, Lee JS, Lee SD, Oh YM: Systematic review and meta-Analysis of pulmonary hypertension specific therapy for exercise capacity in chronic obstructive pulmonary disease. J Korean Med Sci 2013; 28: 1200-1206
40. Andersen CU, Mellemkjaer S, Nielsen-Kudsk JE, Sonderskov LD, Laursen BE, Simonsen U, Hilberg O: Echocardiographic screening for pulmonary hypertension in stable COPD outpatients and NT-proBNP as a rule-out test. COPD 2012; 9: 505-512